Business
Dyadic Reports 2020 Year End Results and Recent Company Progress
Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe
About this update from Dyadic International, Inc.
[{"type":"text","content":"Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercializationTo serve as proof of concept for next-generation multivalent COVID-19 vaccine candidatesExpanded Korea and Southeast Asia vaccine development partnership with Medytox (086900) (KOSDAQ) focused on next-generation COVID-19 variant vaccines and/or boostersIn parallel with DYAI-100, additional proprietary and third-party COVID-19 variant vaccine candidates are under developmentDeveloping a number of other infectious disease vaccines and antibodies internally and in conjunction with others Expanding commercial opportunities of C1 technology through eleven new and two expanded collaborations for human and animal health applications C1 selected by ZAPI (Zoonosis Anticipation Preparedness Initiative) as a vaccine manufacturing platform for more efficient production of antigens that are safe, effective, and protectiveCash and investment grade securities of $29.2 million at year-end 2020JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. (\"Dyadic\", \"we\", \"us\", \"our\", or the \"Company\") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs and other commercial products at flexible commercial scales, today announced its financial results for 2020 and recent business highlights.\"We are very pleased with substantial progress made thus far in 2021 and over the course of 2020. With the ongoing challenges of the COVID-19 pandemic, we have been working tirelessly to identify ways to apply our C1 technology to help speed the development, increase availability, and lower the cost of COVID-19 vaccines and treatments to make them affordable and available worldwide. We and our collaborators worked conscientiously to introduce the C1 technology to the world to enable as many COVID-19 programs as possible and we are continuing to do so as COVID-19 variants continue to emerge. Due to our success in several animal studies where rapidly engineered C1-cells have achieved high levels of antigen productivity and were s...